Dexcom

Glutality powered by StrideMD Announces Integration with Dexcom to Enhance Remote Diabetes Care with CGM Technology

Retrieved on: 
星期二, 四月 30, 2024
BOCA, Health, Multimedia, Dexcom, Electronic health record, CGM, Diabetes, Ecosystem, Patient, G6, Medical device

Glutality is compatible with the Dexcom G6 and Dexcom G7 CGM systems, which provide personalized, actionable glucose insights for people with diabetes and their care teams.

Key Points: 
  • Glutality is compatible with the Dexcom G6 and Dexcom G7 CGM systems, which provide personalized, actionable glucose insights for people with diabetes and their care teams.
  • StrideMD combines its local physician practice presence with an innovative remote care platform that integrates with an ecosystem of EHRs, data partners, and devices.
  • The integration with Dexcom will enhance Glutality's ability to offer real-time glucose data, empowering clinicians to make informed decisions and provide superior support for patients managing diabetes.
  • For more information about how Glutality powered by StrideMD is revolutionizing diabetes care, visit www.StrideMD.com and stay connected through our ongoing journey to transform healthcare through advanced technology and personalized care.

Dexcom Reports First Quarter 2024 Financial Results

Retrieved on: 
星期四, 四月 25, 2024
Health, Medical Devices, Diabetes, Biometrics, Other Health, General Health, Biotechnology, Table, FDA, International, Dexcom, CGM, Webcast, DXCM, Direct, Eastern Time Zone, Adjustment, ID, GAAP, Video game

DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.

Key Points: 
  • DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.
  • First Quarter 2024 Financial Highlights:
    Revenue grew 24% year-over-year to $921.0 million on a reported basis and 25% year-over-year on an organic1 basis.
  • “Dexcom is off to a great start in 2024, delivering another quarter of strong financial results while advancing several key strategic initiatives,” said Kevin Sayer, Dexcom’s chairman, president and CEO.
  • Non-GAAP operating income* for the first quarter of 2024 was $140.2 million, compared to non-GAAP operating income of $78.6 million for the first quarter of 2023.

IDTechEx Examines the Opportunities for Wearables in Digital Health

Retrieved on: 
星期五, 四月 19, 2024
FDA, Sleep apnea, Omron, Sleep disorder, Food, Travel, Health, Dexcom, Diabetes, CGM, Respiratory rate, Medtech, Artificial intelligence, Intelligence, Artificiality, Samsung Galaxy Watch, Digital health, Patient, Electronics, Movement, Metabolism, Athlete, Quality of life, Sleep

IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.

Key Points: 
  • IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.
  • The IDTechEx report on digital health discusses opportunities for consumer health wearables, including key value propositions and a roadmap for wearable sensor technology segmented by key biometrics.
  • IDTechEx's report on digital health covers the intersection of the digital health, diabetes, and consumer markets and includes a 10-year forecast for the CGM market from 2024 – 2034.
  • The consumer health wearables narrative is only one of several stories that IDTechEx covers in " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ".

IDTechEx Examines the Opportunities for Wearables in Digital Health

Retrieved on: 
星期五, 四月 19, 2024
FDA, Sleep apnea, Omron, Sleep disorder, Food, Travel, Health, Dexcom, Diabetes, CGM, Respiratory rate, Medtech, Artificial intelligence, Intelligence, Artificiality, Samsung Galaxy Watch, Digital health, Patient, Electronics, Movement, Metabolism, Athlete, Quality of life, Sleep

IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.

Key Points: 
  • IDTechEx's report, " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ", covers this ongoing trend in the consumer health wearables market and includes analysis of the opportunities and roadmap for biometric monitoring.
  • The IDTechEx report on digital health discusses opportunities for consumer health wearables, including key value propositions and a roadmap for wearable sensor technology segmented by key biometrics.
  • IDTechEx's report on digital health covers the intersection of the digital health, diabetes, and consumer markets and includes a 10-year forecast for the CGM market from 2024 – 2034.
  • The consumer health wearables narrative is only one of several stories that IDTechEx covers in " Digital Health and Artificial Intelligence 2024-2034: Trends, Opportunities, and Outlook ".

Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer

Retrieved on: 
星期一, 四月 8, 2024
Speech, GSK plc, Dexcom, ALS, Paralysis, Diabetes, Patient, Conditional sentence, Instrument, Heel, Electronics, Research, Otis, News, University, Computer engineering, Electricity, G7, Precision, FDA, Movement, Medical device

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.
  • He was one of the co-founders of Verily, Alphabet Inc.’s healthcare and life sciences company, where he served as Chief Technical Officer and Fellow from 2015 through 2022.
  • He oversaw a large, multidisciplinary team in the end-to-end development of new medical technology, from discovery to manufacturing.
  • Under Otis’ technical leadership, Verily entered a number of significant collaborations with leading healthcare and pharmaceutical partners.

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time

Retrieved on: 
星期二, 四月 2, 2024
General Health, Diabetes, Medical Devices, Health, Health Technology, International, Webcast, Eastern Time Zone, DXCM, Dexcom

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024.
  • Management will hold a conference call to review the company's first quarter 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day.
  • The conference call will be concurrently webcast.
  • The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.

Global Smart Insulin Pens Market 10 Year Forecast Report 2024-2034 - A USD 2.30 Billion Market by 2034 with a 10% CAGR During 2024-2034

Retrieved on: 
星期四, 三月 28, 2024
Diabetes, CGM, Sanofi, Eli Lilly, Prevalence, Dexcom, Data analysis, Incidence, Partnership, Insulin, Patient, Continuous glucose monitor, Prescription, Novo Nordisk, Investment, Research report, USD, Pharmaceutical industry

DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 28, 2024 /PRNewswire/ -- The "Global Smart Insulin Pens Market" report has been added to ResearchAndMarkets.com's offering.
  • The global smart insulin pens market accounted for USD 0.769 billion in 2023 and is expected to reach at USD 2.30 billion by 2034 with a CAGR of 10.47% during the forecast period 2024-2034.
  • Diabetes, particularly types 1 and 2, is becoming more common, which has increased demand for cutting-edge and effective insulin administration systems like smart insulin pens.
  • Advanced technology like Bluetooth connectivity, smartphone applications, and electronic dose-tracking features are all integrated into smart insulin pens.

Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy

Retrieved on: 
星期五, 三月 8, 2024
Research, General Health, Technology, Medical Devices, Other Manufacturing, Health Technology, Clinical Trials, Science, Biotechnology, Wearables, Mobile Technology, Health, Diabetes, Manufacturing, TIR, Dexcom, CGM, Doctor of Philosophy, Randomized controlled trial, MD, Treatment, Medical director, G6, AID, Intervention, Conference, ATTD, Safety, Hypoglycemia, Control, RCT, T1D, Corporation, DKA, Body mass index, Treatment and control groups, Pharmaceutical industry

The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.

Key Points: 
  • The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy.
  • "Omnipod 5 continues to demonstrate impressive clinical outcomes for people with type 1 diabetes,” said Professor Renard.
  • The control group (n=62) continued to use their usual insulin pump with a Dexcom G6 CGM, while the intervention group (n=132) used Omnipod 5 with Dexcom G6.
  • In conclusion, this multi-national, RCT data demonstrates the superiority of the Omnipod 5 AID System compared to standard pump therapy with CGM and indicates that it should be offered as a first-line therapy for adults with type 1 diabetes.

Dexcom Announces Upcoming Conference Presentation

Retrieved on: 
星期二, 二月 27, 2024
Diabetes, Health, Medical Devices, Dexcom, DXCM, Webcast, Conference, Broadcasting

DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th.

Key Points: 
  • DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James Institutional Investors Conference on Tuesday, March 5th.
  • The live presentation is scheduled to begin at approximately 8:40 AM EST and will be concurrently webcast.
  • Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.

Green Dot Appoints Michael Meston as Chief Human Resources Officer

Retrieved on: 
星期一, 二月 26, 2024
Software, Internet, Payments, Finance, Banking, Professional Services, Technology, Fintech, Head, Dexcom, Intel, Bruker, Growth, Western Digital, Credibility, As a service, Workforce, GDOT, Green Dot Corporation, Research, Management

Green Dot Corporation (NYSE: GDOT), a leading digital bank and fintech powering consumers and businesses with seamless banking and payment solutions, today announced the appointment of Michael Meston as Chief Human Resources Officer.

Key Points: 
  • Green Dot Corporation (NYSE: GDOT), a leading digital bank and fintech powering consumers and businesses with seamless banking and payment solutions, today announced the appointment of Michael Meston as Chief Human Resources Officer.
  • “Michael is a proven human resources leader with the right experience in organizational change and talent development to help lead Green Dot as we build a workforce committed to seamlessly connecting more people and businesses to their money,” said George Gresham, Chief Executive Officer, Green Dot Corporation.
  • Prior to Bruker Corporation, Meston held senior human resources roles at Dexcom, Western Digital and Intel across the United States and Asia.
  • “Green Dot is enabling a generational shift in how consumers and businesses are accessing and utilizing financial services, and I am excited to contribute to that vision,” said Meston.